[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc reported a Form 144 notice for the proposed sale of 11,000 Class A ordinary shares to be executed through Charles Schwab & Co., Inc. on 09/03/2025 with an aggregate market value of $383,203.00. The shares were acquired the same day via an employee stock option exercise and the transaction will use a broker payment for a cashless exercise. The filing lists 43,472,928 shares outstanding, and shows prior sales by Michael R. Megna of 15,211 shares on 06/03/2025 (gross proceeds $437,330) and 17,000 shares on 08/04/2025 (gross proceeds $549,936). The filer certifies no undisclosed material adverse information.

Positive

• Rule 144 disclosure completed, providing regulatory transparency
• Securities were acquired via documented employee stock option exercise
• Filing includes past insider sales with specific gross proceeds

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider exercised options and plans a Rule 144 sale of 11,000 shares; prior small insider sales noted.

The filing shows an insider exercise followed immediately by a planned Rule 144 sale using a broker cashless exercise mechanism. The sale size (11,000 shares) is small relative to the reported 43.47 million shares outstanding, indicating limited direct dilution or market impact. Two recent insider dispositions are disclosed with combined gross proceeds of $987,266, which is informative for trading flow but not necessarily material to company fundamentals.

Corporate Governance Expert

TL;DR: The notice satisfies disclosure requirements; multiple recent insider sales warrant routine monitoring.

The Form 144 provides the necessary Rule 144 transparency and includes representations about absence of undisclosed material information. Repeated insider sales are documented, which is appropriate under SEC rules; governance observers may note the pattern but the absolute sizes disclosed are modest versus total outstanding shares, suggesting limited governance concern based solely on this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	11000	383203.00	43472928	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	09/03/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			11000	09/03/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael R Megna 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/03/2025	15211	437330.00
Michael R Megna 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	08/04/2025	17000	549936.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the KNSA Form 144?

The filing reports a proposed sale of 11,000 Class A ordinary shares to be sold on 09/03/2025 through Charles Schwab with an aggregate market value of $383,203.00.

How were the 11,000 shares acquired according to the filing?

The shares were acquired on 09/03/2025 by an employee stock option exercise and the payment method is listed as a broker payment for a cashless exercise.

Who conducted prior sales disclosed in the filing and what were the proceeds?

The filing lists prior sales by Michael R. Megna: 15,211 shares on 06/03/2025 for $437,330 and 17,000 shares on 08/04/2025 for $549,936.

How large is the issuer's outstanding share count reported in the notice?

The filing reports 43,472,928 shares outstanding.

Does the filer represent possession of undisclosed material information?

Yes. By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.